Navigation Links
Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference
Date:1/4/2012

PALO ALTO, Calif., Jan. 4, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate update at the 5th Annual OneMedForum Conference on Wednesday, January 11 at 12:00 p.m. Pacific time (3:00 p.m. Eastern time) in San Francisco.  A live and archived webcast of the presentation will be available on the Telik website, www.telik.com.  The archived broadcast of the presentation can be accessed for 30 days following the presentation.

About Telik
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome
2. Telik Announces Presentation and Webcast at 12th Annual BIO CEO & Investor Conference
3. Telik Announces Second Quarter 2009 Financial Results
4. Telik Reports Preclinical Results at AACR Annual Meeting
5. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
6. Telik Announces New TRAP Drug Discovery Agreement
7. Telik Announces Financial Results for 2008 Third Quarter
8. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
9. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
10. Telik Announces Receipt of Nasdaq Notice
11. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):